Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy
TAIPEI and SAN DIEGO, Dec. 29, 2025 /PRNewswire/ -- Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its marketed PD-1 inhibitor in the challenging field of...
CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596
SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted two separate Investigational New Drug (IND)...
Z.ai Releases GLM-4.7 Designed for Real-World Development Environments, Cementing Itself as "China's OpenAI"
BEIJING, Dec. 27, 2025 /PRNewswire/ -- On December 22, Z.ai released GLM-4.7, the latest iteration of its GLM large language model family. Designed to handle multi-step tasks in production, GLM-4.7 targets development environments that involve...
China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR)...
MMA Announces SMARTIES™ X Global 2025 Winners: Honoring Marketing That Drives Global Impact
NEW YORK, Dec. 19, 2025 /PRNewswire/ -- The Marketing + Media Alliance (MMA) proudly announces the winners of the SMARTIES™ X Global 2025 Awards, recognizing the world's most effective and innovative marketing campaigns. This year's program...
Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly superior...
Comarch Named a Strong Performer in Loyalty Platforms Evaluation by Independent Research Firm
KRAKÓW, Poland, Dec. 9, 2025 /PRNewswire/ -- Comarch, a global provider of IT solutions and services, today announced its recognition as a Strong Performer in The Forrester Wave™: Loyalty Platforms, Q4 2025. The report, authored by John Pedini,...
Why Transparent, Comparable, and Reliable Security Testing Matters: AV-Comparatives Highlights 2025 Enterprise EPR and EDR Results
INNSBRUCK, Austria, Dec. 9, 2025 /PRNewswire/ -- As cyberattacks continue to challenge even the most resilient organisations, the need for clear, trustworthy, and openly documented security testing has never been more critical. AV-Comparatives,...
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product...
Lunit to Highlight New AI Evidence in Cancer Screening and Breast Density-Driven Risk Modeling at RSNA 2025
Eight oral presentations and six posters demonstrate advances in mammography, DBT performance, and density-informed risk modeling SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision...